NewsStjepan Kalinic
VanEck Pharmaceutical ETF
PPH · ETF
$116.34+$2.86 (+2.52%)TodayMarket closed ·
Prev close $113.48
Latest news
- NewsVandana Singh
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery
- NewsNabaparna Bhattacharya
What's Going On With Merck Stock Tuesday?
- NewsRishabh Mishra
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
- NewsChandrima Sanyal
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk
- NewsChandrima Sanyal
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight
- NewsChandrima Sanyal
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs
- NewsRishabh Mishra
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
- NewsChandrima Sanyal
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
- NewsChandrima Sanyal
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet
- NewsRishabh Mishra
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
- NewsRishabh Mishra
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
- NewsRishabh Mishra
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
- NewsRishabh Mishra
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
- NewsChandrima Sanyal
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
- Press releaseBusiness Wire
VanEck Announces Year-End Distributions for VanEck Equity ETFs
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.